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Abstract 
DLX2 belongs to the six-member family of DLX 
genes characterized by a homeobox related to that 
found in the insect Distal-less (Dll) gene. It was the 
first human homologue to be discovered (Selski et 
al., 1993; McGuinness et al., 1996).  
The six DLX genes are organized as three bigenic 
pairs with a tail-to-tail orientation (Zerucha et al., 
2000) and located on chromosomes where HOX 
clusters are also found (DLX5/DLX6; 7q21.3, 
syntenic to the HOXA cluster), (DLX1/DLX2; 
2q32 syntenic to the HOXD cluster; Simeone et al., 
1994; Zerucha et al., 2000) and (DLX3/DLX4; 
17q21.33 syntenic to the HOXB cluster).  
During embryonic development DLX genes are 
involved in the control of appendage and 
craniofacial morphogenesis and in the 
differentiation of reproductive organs; in the adult 
they play a role in bone homeostasis and in the 
maintenance of tissue  
 
integrity (Kraus and Lufkin, 2006). 
Identity 
Other names: TES-1, TES1 
HGNC (Hugo): DLX2 
Location: 2q31.1 
Local order 
Reverse strand of human chromosome 2, from 
172964167 to 172967628 - see Figure 1 below. 
DLX2 forms a bigenic cluster with DLX1 at 2q31. 
DNA/RNA 
Note 
DLX2 is in an inverted convergent orientation from 
DLX1, with both exons 3 separated by 10.7 kb 
where two enhancers have been identified and 
functionally characterized (Zerucha et al., 2000; 
Sumiyama et al., 2002; Ghanem et al., 2003; Park 
et al., 2004).  
 
Figure 1. Genomic context of the human DLX1/DLX2 bigenic locus. 
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Figure 2. The two known human DLX2 transcripts. 
 
 
While one regulatory element is enough and 
sufficient to drive proper and full expression of 
Dlx1/Dlx2 genes based upon mouse reporter 
assays, other, extragenic elements are involved in 
the dual regulation of Dlx1 and Dlx2. 
The imprinting status of the DLX1/DLX2 locus has 
received much less attention than that of their 
DLX5/DLX6 paralogs (see their respective cards). 
However, an epigenetic mechanism linking Dlx2 
function with neural stem cell maintenance has 
been demonstrated in adult mice (Lim et al., 2009). 
Chromatin immunoprecipitation assays 
differentiating subventricular zone neural stem cells 
has shown that the Dlx2 locus is a direct bivalent 
target of the histone methyltransferase Mll1 
(mixed-lineage leukemia 1). Whether such 
methylation process has a clinical relevance 
remains to be determined, as altered methylation of 
DLX2 has been observed in pathogenic conditions, 
including in primary cells from brain astrocytomas, 
where hypermethylation of DLX2 CpG island has 
been observed (Wu et al., 2010). 
Transcription 
Transcription from DLX2 yields two splice variants 
which share the first two exons, the homeodomain 
and the N-terminal DLL domain (see Figure 2). The 
major, mature isoform encodes a 328 AA long 
transcription factor (34.2 kDa and pI 9.25). Sense 
isoforms have not been reported for this gene. 
Protein 
Description 
The major DLX2 isoform is a 328 AA helix-turn-
helix homeodomain transcription factor (34.2 kDa 
and pI 9.5). The ultraconserved homeobox domain 
spans exons 1 and 2 at 153-211. A second N-
terminal DNA binding domain, specific to the 
DLX2/3/5 clade within the distal-less family, is 
encoded by exon 1 at AA 51-132. Local 
composition biases include three poly-glycine and 
one poly-histidine stretches, and a phosphorylation 
target serine at 232 (see Figure 3 below). 
Expression 
DLX2 is a predominantly nuclear transcription 
factor, from the helix-turn-helix group. It 
transactivates target gene expression in 
heterodimeric association with other DLX and 
MSX transcription factors. Its consensus binding 
site is TTA(G/A)TTGA. Chromatin 
immunoprecitpitation assays have shown that 
during mouse forebrain development, Dlx2 (along 
with Dlx1) specifically binds an intergenic 
enhancer within the Dlx5/Dlx6 locus (see their 
respective cards), and transactivates their 
expression (Zerucha et al., 2000; Zhou et al., 2004). 
Interestingly, regulation of the Dlx5/Dlx6 locus in 
the developing retina occurs through transactivation 
by Dlx2 but not Dlx1. 
 
Figure 3. Structure of the major DLX2 protein isoform. Note the N- and C-terminal poly-glycine stretches, and the N-terminal 
DLL-like domain. 
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Figure 4. NCBI/COBALT alignment of DLX homeoproteins. Note the disposition according to the DLX 1/4/6 versus DLX 2/3/5 




A particularity of Dlx2 is its ability to cooperate 
with a nuclear non-coding RNA (sense and single-
stranded, 440 b), Evf-2, transcribed from the 
Dlx5/Dlx6 locus, to form a stable complex which 
binds and transactivates both Dlx5/6 intergenic 
enhancers (Feng et al., 2006).  
While such an RNA/homeoprotein cooperativity 
has been demonstrated for other factors (Dubnau 
and Struhl, 1996), it has not been reported so far for 
other Dlx family members. 
On the other hand, Dlx2 has been shown to 
autorepress its expression during mouse tooth 
formation when expressed alone, while 
autoactivating it when expressed in combination 
with PitX2 (Venugopalan et al., 2011).  
This observation lends support to the notion that the 
transcriptional activity of DLX factors often 
depends upon cooperative binding with other 
homeproteins, including from the PTX and MSX 
families (Zhang et al., 1997; Vieux-Rochas et al., 
2013). 
Homology 
With regards to other members of the DLX family, 
DLX2 belongs to the DLX2/3/5 clade based on 
sequence homology (see Figure 4). It shares an N-
terminal DLL-like domain specific to this clade. 
The homeodomain sequence remains close to the 
other DLX proteins. 
Implicated in 
Breast tumors and their metastases 
to bone and lung tissues 
Note 
Neoplastic processes often result from 
combinatorial activity of developmental genes 
(Abate-Shen, 2002). Dysregulated expression of 
homeobox-containing genes of the distal-less 
family, arranged as three bigenic pairs in mammals 
(DLX1/2, DLX3/4 and DLX5/6; Kraus and Lufkin, 
2006), has been reported to correlate with distinct 
oncogenic mechanisms.  
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DLX2 is expressed and necessary but insufficient to 
initiate metabolic stress-induced necrosis within 
several solid human high-grade tumors (Lee et al., 
2011). DLX2 is strongly expressed in human 
primary breast tumors, its expression is associated 
with better prognosis and fewer relapses (Morini et 
al., 2010). In contrast, DLX2 expression is lost by 
breast tumor-derived metastatic cells found in lung 
or bone tissues - a poor prognosis marker (Morini et 
al., 2010). The combined downregulation of DLX2 
and upregulation of DLX5 might thus prove a 
valuable prognostic marker.  
DLX2 has been observed to be one of several 
homeogenes whose CpG islands were 
hypermethylated in luminal breast cancer cells, at 1 
kb from the transcription start site (Kamalakaran et 
al., 2011). This status has been found to correlate 
significantly with higher expression level of DLX2, 
which lends support to the notion that DLX2 may 
serve as a candidate prognosis marker in breast 
cancer (Morini et al., 2010). 
Solid tumors involving other organs 
Note 
Induction of DLX2 expression has been further 
reported in other solid tumors, including promoting 
advanced gastric adenocarcinoma (Tang et al., 
2013), promoting growth from lung, prostate and 
glioma tumors, and correlates with melanoma 
malignancy (Yilmaz et al., 2011; Yan et al., 2013). 
It appears that at least one member of each DLX 
bigenic pair (DLX2, DLX5 and DLX4 : see Hara et 
al., 2007) is closely implicated with solid 
tumorigenicty. 
Acute lymphoblastic leukemia 
Note 
Conversely, DLX2 expression is lost along with 
DLX3 and DLX4 in samples from patients afflicted 
by acute lymphoblastic leukemia with 
t(4;11)(q21;q23) chromosomal abnormality (Ferrari 
et al., 2003). In the same paper it is also shown that 
Dlx genes participate to the regulatory cascade 
initiated by acute lymphoblastic leukemia (ALL)-1, 
a recurring partner of translocations involving 
chromosome band 11q23 in human biphenotypic 
leukemias. 
Autism spectrum disorder 
Note 
Autism has been recognized as a condition which 
may result from an imbalance between inhibitory 
and excitatory processes in the developing and 
mature brain. Dlx1 and Dlx2 control the 
specification, fate and metabolic function of a 
subset of neurons known to exert an inhibitory role 
in the brain. As part of a cascade of homeobox-
containing genes controlling neuronal specification 
in the brain, the DLX1/2 locus has thus been 
examined for association with autism spectrum 
disorder. Extensive coverage of both coding and 
intergenic sequences among a large cohort of 
autistic probands has uncovered only a handful of 
non-synonymous variants - which nevertheless 
provides a strong set of functional candidates to 
assess whether disrupted DLX2 expression might 
play a role in autism (Hamilton et al., 2005). More 
recently, a large cohort study has pinpointed 
stronger candidate sites of polymorphism correlated 
with increased susceptibility to develop the 
neurologic condition (Liu et al., 2009) - however a 
direct functional impact remains to be evidenced. 
Interestingly, DLX2 was found to harbour 
trinucleotide repeats but as for its DLX6 paralog, 
family-based association analysis ruled out this 
polymorphism as a risk variant, in either autism or 
schizophrenia patients (Laroche et al., 2008). 
Dysmorphogenesis 
Note 
Although mouse embryos invalidated for Dlx1 
and/or Dlx2 display craniofacial abnormalities, a 
direct involvement of DLX1/DLX2 mutation in 
human malformations remains to be demonstrated. 
For instance, while synpolydactyly has been tightly 
linked to DLX2 (Sarfarazi et al., 1995), it is the 
lack of induction of its promoter by defective 
PITX2 which has been demonstrated to directly 
cause Axenfeld-Rieger syndrome (ARS, OMIM 
#180500) - an autosomal dominant condition 
featuring a wide range of tooth anomalies, 
maxillary hypoplasia, and eye malformation 
(Espinoza et al., 2002). 
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